US5770592A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention and treatment of ocular neovascularization using angiostatic steroids
Assignee: Alcon Research LLC
•
Filing: 1997-07-16
•
Granted: 1998-06-23
•
Expires: 2017-07-16
Abstract
Abstract Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.
Inventors
- 👤 Abbot F. Clark
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 08:31
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K31/573; A61K31/565; A61P; A61P27/00; A61P27/02; C; C07; C07J; C07J11/00; C07J3/00; C07J41/00; C07J41/0005; C07J41/0027; C07J5/00; C07J5/0046; C07J5/0053; C07J51/00; C07J9/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
97 words
A method for preventing and treating the ocular neovascularization associated with conditions or diseases selected from the group consisting of diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, rubeosis iritis, uveitis, neoplasms, Fuchs' heterochromic iridocyclitis, neovascular glaucoma, corneal neovascularization, neovascularization resulting from combined vitrectomy and lensectomy, retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, carotid artery ischemia, and contusive ocular injury, which comprises: administering, topically, systemically, or intraocularly, to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol3,20-dione,11-Epicortisol, 17 alpha-Hydroxprogesterone, and Tetrahydrocortexolone (THS).
Claim 2
Independent Claim
97 words
A method for preventing and treating the ocular neovascularization associated with conditions or diseases selected from the group consisting of diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, rubeosis iritis, uveitis, neoplasms, Fuchs' heterochromic iridocyclitis, neovascular glaucoma, corneal neovascularization, neovascularization resulting from combined vitrectomy and lensectomy, retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, carotid artery ischemia, and contusive ocular injury, which comprises: administering, topically, systemically, or intraocularly, to a host in need thereof, a pharmaceutically effective amount of an angiostatic steroid selected from the group consisting of: 4,9(11)-Pregnadien-17a,21-diol3,20-dione,11-Epicortisol, 17 alpha-Hydroxprogesterone, and Tetrahydrocortexolone (THS).
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17a, 21-diol-3,20-dione-21-acetate.
Claim 4
Dependent Claim
12 words
The method of claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17a, 21-diol-3,20-dione.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein the angiostatic steroid is administered at a concentration of about 0.01 to 10.0 weight percent.
Claim 6
Dependent Claim
19 words
The method of claim 4 wherein the angiostatic steroid is administered at a concentration of about 0.1-5.0 weight percent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-22 | 2001-12-22 | 2002-06-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-22 | 2005-12-22 | 2006-06-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-22 | 2009-12-22 | 2010-06-23 | $7700.00 | Window Closed / Lapsed |